Drug duo targets rare HER2 cancers in new trial
NCT ID NCT06136897
First seen Dec 16, 2025 · Last updated May 15, 2026 · Updated 22 times
Summary
This study tests whether combining two targeted drugs, trastuzumab and pertuzumab, can shrink or control cancers that have too much of a protein called HER2. It includes adults with solid tumors that are not breast, stomach, or colorectal cancers. The goal is to see if this drug pair works for these less common HER2-positive cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.